Compass Therapeutics (NASDAQ:CMPX) Receives Outperform Rating from Wedbush

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a research note issued to investors on Tuesday,RTT News reports. They currently have a $8.00 price objective on the stock. Wedbush’s price target points to a potential upside of 257.14% from the company’s current price.

Several other research firms have also issued reports on CMPX. Piper Sandler initiated coverage on Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective on the stock. Jefferies Financial Group boosted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. D. Boral Capital restated a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday. Guggenheim assumed coverage on Compass Therapeutics in a research report on Monday, February 24th. They issued a “buy” rating and a $12.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $11.38.

Compass Therapeutics Stock Performance

Shares of CMPX traded up $0.34 during mid-day trading on Tuesday, reaching $2.24. 22,342,215 shares of the company’s stock traded hands, compared to its average volume of 779,425. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $4.08. The stock has a market capitalization of $309.75 million, a P/E ratio of -6.05 and a beta of 1.19. The business’s 50-day moving average price is $2.83 and its 200-day moving average price is $2.11.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Equities research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMPX. Squarepoint Ops LLC bought a new stake in Compass Therapeutics during the fourth quarter valued at about $35,000. Tang Capital Management LLC lifted its holdings in shares of Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after buying an additional 4,087,005 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Compass Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares during the period. MPM Bioimpact LLC boosted its holdings in Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock valued at $12,423,000 after purchasing an additional 2,926,002 shares during the period. Finally, Enavate Sciences GP LLC acquired a new stake in Compass Therapeutics during the fourth quarter worth about $11,293,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.